Selected research
Industry Research
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Research Report 2026
Market perspective
The global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs include Teva, Novartis, Merck, Pfizer, Amgen, SL Pharm, North China Pharmaceutical, Kyowa Kirin and Intas, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Company
Teva
Novartis
Merck
Pfizer
Amgen
SL Pharm
North China Pharmaceutical
Kyowa Kirin
Intas
Hayao Group
GenSci
Dr. Reddy
Dong-A Socio
Chugai Pharmaceutical
Amoytop
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Type
Filgrastim
Lipefigrastim
Pefigrastim
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Application
Oncology
Blood Disease
Other
Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Filgrastim
- Lipefigrastim
- Pefigrastim
Applications
- Oncology
- Blood Disease
- Other
Companies covered
- Teva
- Novartis
- Merck
- Pfizer
- Amgen
- SL Pharm
- North China Pharmaceutical
- Kyowa Kirin
- Intas
- Hayao Group
- GenSci
- Dr. Reddy
- Dong-A Socio
- Chugai Pharmaceutical
- Amoytop
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Filgrastim
- 2.2.3 Lipefigrastim
- 2.2.4 Pefigrastim
- 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Blood Disease
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Breakdown Data by Type
- 3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Type (2027-2032)
4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Breakdown Data by Application
- 4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Perspective (2021-2032)
- 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Growth Trends by Region
- 5.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Dynamics
- 5.3.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends
- 5.3.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Drivers
- 5.3.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Challenges
- 5.3.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Revenue
- 6.1.1 Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Head Office and Area Served
- 6.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players, Product Type & Application
- 6.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Manufacturers Established Date
- 6.6 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
- 7.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
- 7.4 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
- 8.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
- 8.4 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
- 10.2 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
- 10.4 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.1.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.2.4 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.3.4 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Pfizer
- 12.4.1 Pfizer Company Information
- 12.4.2 Pfizer Business Overview
- 12.4.3 Pfizer Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.4.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.4.5 Pfizer Recent Developments
- 12.5 Amgen
- 12.5.1 Amgen Company Information
- 12.5.2 Amgen Business Overview
- 12.5.3 Amgen Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.5.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.5.5 Amgen Recent Developments
- 12.6 SL Pharm
- 12.6.1 SL Pharm Company Information
- 12.6.2 SL Pharm Business Overview
- 12.6.3 SL Pharm Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.6.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.6.5 SL Pharm Recent Developments
- 12.7 North China Pharmaceutical
- 12.7.1 North China Pharmaceutical Company Information
- 12.7.2 North China Pharmaceutical Business Overview
- 12.7.3 North China Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.7.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.7.5 North China Pharmaceutical Recent Developments
- 12.8 Kyowa Kirin
- 12.8.1 Kyowa Kirin Company Information
- 12.8.2 Kyowa Kirin Business Overview
- 12.8.3 Kyowa Kirin Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.8.4 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.8.5 Kyowa Kirin Recent Developments
- 12.9 Intas
- 12.9.1 Intas Company Information
- 12.9.2 Intas Business Overview
- 12.9.3 Intas Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.9.4 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.9.5 Intas Recent Developments
- 12.10 Hayao Group
- 12.10.1 Hayao Group Company Information
- 12.10.2 Hayao Group Business Overview
- 12.10.3 Hayao Group Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.10.4 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.10.5 Hayao Group Recent Developments
- 12.11 GenSci
- 12.11.1 GenSci Company Information
- 12.11.2 GenSci Business Overview
- 12.11.3 GenSci Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.11.4 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.11.5 GenSci Recent Developments
- 12.12 Dr. Reddy
- 12.12.1 Dr. Reddy Company Information
- 12.12.2 Dr. Reddy Business Overview
- 12.12.3 Dr. Reddy Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.12.4 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.12.5 Dr. Reddy Recent Developments
- 12.13 Dong-A Socio
- 12.13.1 Dong-A Socio Company Information
- 12.13.2 Dong-A Socio Business Overview
- 12.13.3 Dong-A Socio Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.13.4 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.13.5 Dong-A Socio Recent Developments
- 12.14 Chugai Pharmaceutical
- 12.14.1 Chugai Pharmaceutical Company Information
- 12.14.2 Chugai Pharmaceutical Business Overview
- 12.14.3 Chugai Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.14.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.14.5 Chugai Pharmaceutical Recent Developments
- 12.15 Amoytop
- 12.15.1 Amoytop Company Information
- 12.15.2 Amoytop Business Overview
- 12.15.3 Amoytop Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2021-2026)
- 12.15.4 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
- 12.15.5 Amoytop Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst